44.05USD
9 Feb 2010
$1.79 (+4.23%)
$44.05
--
$44.05
$44.05
500
982
$50.45
$30.20
AZNCF.PK
About
Overall
| Beta: | 0.47 |
| Market Cap (Mil.): | $40,852.91 |
| Shares Outstanding (Mil.): | 1,451.00 |
| Annual Dividend: | -- |
| Yield (%): | -- |
Financials
| AZNCF.PK | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 8.48 | 1.96 | 3.76 |
| EPS (TTM): | 23.58 | -- | -- |
| ROI: | 21.40 | 0.92 | 2.30 |
| ROE: | 41.13 | 1.27 | 2.82 |
UPDATE 2-Sanofi says vaccines to help lift 2010 earnings
* Q4 adj net income 1.8 bln euros vs Reuters poll 1.68 bln
Researchers find sex-specific lung cancer genes
WASHINGTON (Reuters) - Lung cancer is often dramatically different in women than it is in men, U.S. researchers reported on Tuesday in another study that suggests ways to tailor treatment for cancer patients.
Researchers find sex-specific lung cancer genes
WASHINGTON, Feb 9 (Reuters) - Lung cancer is often dramatically different in women than it is in men, U.S. researchers reported on Tuesday in another study that suggests ways to tailor treatment for cancer patients.
European shares drift higher, Greece jitters persist
LONDON, Feb 9 (Reuters) - European shares edged higher on Tuesday, led by banks though investors remained wary of the debt problems in Greece and other peripheral euro zone economies.
STOCKS NEWS UK-Patsystems up on strong FY, outlook
STOCKS NEWS Reuters Results diary
Astra gets Crestor boost
LONDON (Reuters) - AstraZeneca has pulled ahead of the pack with an expanded label in the United States for its heart drug Crestor, but the medicine's future remains uncertain ahead of a vital patent trial this month.
UPDATE 1-Astra gets Crestor boost ahead of key patent trial
(Adds details on patent case, further analyst comment)
STOCKS NEWS UK-Rightmove rises on 2010 profit outlook
.STOCKS NEWS Reuters Results diary
STOCKS NEWS EUROPE-AstraZeneca up on broad Crestor label
AstraZeneca shares gain 1.5 percent, outperforming a flat European drugs sector , after U.S. approval for expanded use of Crestor strengthens its position in the highly competitive cholesterol drug market.
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
